Fused Bicyclic Gly-Asp β-Turn Mimics with Specific Affinity for GPIIb-IIIa
Matthew J. Fisher(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), J. M. JUN. MORIN, Bruce P. Gunn(Eli Lilly (United States)), Robert M. Scarborough(Scripps Research Institute), Michael Möhr(Johannes Gutenberg University Mainz), M. D. KINNICK, Cathy S. Harms(Eli Lilly (United States)), Terry D. Lindstrom(Eli Lilly (United States)), Daniel J. Sall(Eli Lilly (United States)), Birgit Sommer(Eli Lilly (United States)), Robert T. Vasileff, Michael J. Martinelli(Eli Lilly (United States)), Ann E. Arfstan(Eli Lilly (United States)), Theo Schotten, Silke Vöelkers(Eli Lilly (United States)), Michael Paal, Gerd Rühter, Jeffrey T. Mullaney(Eli Lilly (United States)), Achim Rapp, Ken J. Ruterbories(Eli Lilly (United States)), Wolfgang Stenzel, Richard D. Towner(Eli Lilly (United States)), Anne Nunes(Eli Lilly (United States)), Suzane L. Um(Eli Lilly (United States)), Hans‐Jürgen Mest, Barbara G. Utterback(Eli Lilly (United States)), Ulrich Giese, Vien V. Khau(Eli Lilly (United States)), Virginia L. Wyss(Eli Lilly (United States))
Cited by 8
Related Papers
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617